Breast Cancer Research and Treatment

, Volume 92, Issue 1, pp 1–9 | Cite as

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

  • George Fountzilas
  • Dimitrios Pectasides
  • Anna Kalogera-Fountzila
  • Dimosthenis Skarlos
  • Haralambos P. Kalofonos
  • Christos Papadimitriou
  • Dimitrios Bafaloukos
  • Stefanos Lambropoulos
  • Savvas Papadopoulos
  • Helen Kourea
  • Christos Markopoulos
  • Helen Linardou
  • Dimitrios Mavroudis
  • Evangelos Briasoulis
  • Nicholaos Pavlidis
  • Evangelia Razis
  • Paraskevas Kosmidis
  • Helen Gogas
Report

Summary

Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for cancer treatment. This multicenter phase II trial treated 68 patients with advanced breast cancer with paclitaxel (175 mg/m2 over 3 h) and 3-weekly carboplatin (area under the curve of 6) for six cycles, and 250 mg/day gefitinib orally. Median age was 57 (range 35–77) years, patients had performance status 0 (69.1%), 1 (27.9%) 2 (2.9%), 82.4% of patients had visceral metastases and 63.2% had received adjuvant chemotherapy. Forty-eight (70.6%) patients completed six cycles of chemotherapy and 20 (29.4%) patients discontinued treatment (seven [10.3%] due to disease progression, seven [10.3%] due to toxicity, five [7.4%] withdrew consent and one [1.5%] died after the first cycle). Sixty-three (92.7%) patients were evaluable for response; nine (13.2%) had complete responses, 30 (44.1%) had partial responses, 21 (30.9%) had stable disease and three (4.4%) had disease progression. Grade 3/4 adverse events in ≥5% of patients except of alopecia, included neutropenia (17.7%), anemia (10.3%), diarrhea (7.4%), thrombocytopenia (5.9%) and peripheral neuropathy (5.9%). Of those tumor biopsies available for immunohistochemical analysis (n=60), 5.0% were positive and 35.0% negative for expression of all HER-family receptors. Comparable numbers of tumor biopsies were nuclear p27kipl positive and negative (39.7 and 42.7%, respectively), with the majority (72.1%) negative for cytoplasmic p27kipl. The observed efficacy data in this study were similar to those reported for the combination of paclitaxel and carboplatin alone.

Keywords

advanced breast cancer carboplatin gefitinib IRESSA paclitaxel 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Shaughnessy, J, Miles, D, Vukelja, S, Moiseyenko, V, Ayoub, JP, Cervantes, G, Fumoleau, P, Jones, S, Lui, WY, Mauriac, L, Twelves, C, Van Hazel, G, Verma, S, Leonard, R 2002Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJ Clin Oncol2028122823PubMedGoogle Scholar
  2. 2.
    Fountzilas, G, Athanassiades, A, Kalogera-Fountzila, A, Aravantinos, G, Bafaloukos, D, Briasoulis, E, Dombros, N, Ioannidis, I, Pavlidis, N, Kosmidis, P, Skarlos, D 1997Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology GroupEur J Cancer3318931895CrossRefPubMedGoogle Scholar
  3. 3.
    Fountzilas, G, Dimopoulos, AM, Papadimitriou, C, Kalogera-Fountzila, A, Aravantinos, G, Bafaloukos, D, Athanassiades, A, Nicolaides, C, Kerampoulos, A, Pavlidis, N, Kosmidis, P, Skarlos, D 1998First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report) a phase II study conducted by the Hellenic Cooperative Oncology GroupAnn Oncol910311034CrossRefPubMedGoogle Scholar
  4. 4.
    Fountzilas G, Kalofonos HP, Dafni U, et al: Paclitaxel and epirubicin versus paclitaxel and carboplatin, as first line chemotherapy in patients with advanced breast cancer, a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol in pressGoogle Scholar
  5. 5.
    Chan, KC, Knox, WF, Gee, JM, Morris, J, Nicholson, RI, Potten, CS, Bundred, NJ 2002Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastCancer Res62122128PubMedGoogle Scholar
  6. 6.
    Chan, KC, Knox, WF, Gandhi, A, Slamon, DJ, Potten, CS, Bundred, NJ 2001Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferationBr J Surg88412418CrossRefPubMedGoogle Scholar
  7. 7.
    Ciardiello, F, Caputo, R, Bianco, R, Damiano, V, Fontanini, G, Cuccato, S, De Placido, S, Bianco, AR, Tortora, G 2001Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitorClin Cancer Res714591465PubMedGoogle Scholar
  8. 8.
    Sirotnak, FM, Zakowski, MF, Miller, VA, Scher, HI, Kris, MG 2000Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinaseClin Cancer Res648854982PubMedGoogle Scholar
  9. 9.
    Ciardiello, F, Caputo, R, Bianco, R, Damiano, V, Pomatico, G, De Placido, S, Bianco, AR, Tortora, G 2000Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitorClin Cancer Res620532063PubMedGoogle Scholar
  10. 10.
    Witton, CJ, Reeves, JR, Going, JJ, Cooke, TG, Bartlett, JM 2003Expression of the HER1-4 family of receptor tyrosine kinases in breast cancerJ Pathol200290297CrossRefPubMedGoogle Scholar
  11. 11.
    Anido, J, Matar, P, Albanell, J, Guzman, M, Rojo, F, Arribas, J, Averbuch, S, Baselga, J 2003ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cellsClin Cancer Res912741283PubMedGoogle Scholar
  12. 12.
    Alkarain, A, Slingerland, J 2004Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerBreast Cancer Res61321CrossRefPubMedGoogle Scholar
  13. 13.
    Clarke, RB 2003p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosisBreast Cancer Res5162163CrossRefPubMedGoogle Scholar
  14. 14.
    Arteaga, CL 2004Cdk inhibitor p27Kip1 and hormone dependence in breast cancerClin Cancer Res10368S371SPubMedGoogle Scholar
  15. 15.
    Hammond, LA 2003Pharmacokinetic evaluation of gefitinib when administered with chemotherapyClin Lung Cancer5S18S21PubMedGoogle Scholar
  16. 16.
    Miller, VA, Johnson, DH, Krug, LM, Pizzo, B, Tyson, L, Perez, W, Krozely, P, Sandler, A, Carbone, D, Heelan, RT, Kris, MG, Smith, R, Ochs, J 2003Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerJ Clin Oncol2120942100CrossRefPubMedGoogle Scholar
  17. 17.
    Jelliffe, RW 1973Creatinine clearance: bedside estimateAnn Intern Med79604605(letter)PubMedGoogle Scholar
  18. 18.
    Calvert, AH, Newell, DR, Gumbrell, LA, O’Reilly, S, Burnell, M, Boxall, FE, Siddik, ZH, Judson, IR, Gore, ME, Wiltshaw, E 1989Carboplatine dosage: prospective evaluation of a simple formula based on renal functionJ Clin Oncol717481756PubMedGoogle Scholar
  19. 19.
    Fountzilas, G, Athanassiades, A, Papadimitriou, V, Dimopoulous, MA, Bafaloukos, D, Aravantinos, G, Nicolaides, C, Kalafonos, H, Papakostas, P, Xiros, N, Razi, E 1998Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancerOncology (Huntingt)124548Google Scholar
  20. 20.
    Perez, EA, Hillman, DW, Stella, PJ, Krook, JE, Hartmann, LC, Fitch, TR, Hatfield, AK, Mailliard, JA, Nair, S, Kardinal, CG, Ingle, JN 2000A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinomaCancer88124131PubMedGoogle Scholar
  21. 21.
    Bailey, LR, Kris, M, Wolf, M, Kay, A, Averbuch, S, Askao, J, Janas, M, Schmidt, K, Fukuoka, M 2003Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2Proc Am Assoc Cancer Res441362(abstract LB-170)Google Scholar
  22. 22.
    Bonomi, P 2003Erlotinib: a new therapeutic approach for non-small cell lung cancerExpert Opin Investig Drugs1213951401CrossRefPubMedGoogle Scholar
  23. 23.
    Yarden, Y, Sliwkowski, MX 2001Untangling the ErbB signalling networkNat Rev Mol Cell Biol2127137CrossRefPubMedGoogle Scholar
  24. 24.
    Ravindranath, N, Wion, D, Brachet, P, Djakiew, D 2001Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostateJ Androl22432443PubMedGoogle Scholar
  25. 25.
    Paez, JG, Jänne, PA, Lee, JC, Tracy, S, Greulich, H, Gabriel, S, Herman, P, Kaye, FJ, Lindeman, N, Boggon, TJ, Naoki, K, Sasaki, H, Fujii, Y, Eck, MJ, Sellers, WJ, Johnson, BE, Meyerson, M 2004EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience30414971500CrossRefPubMedGoogle Scholar
  26. 26.
    Lynch, TJ, Bell, DW, Sordella, R, Gurubhagavantula, S, Okimoto, RA, Brannigan, BW, Harris, PL, Haserlat, SM, Supko, JG, Haluska, FG, Louis, DN, Christiani, DC, Settleman, J, Haber, DA 2004Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med35021912193CrossRefPubMedGoogle Scholar
  27. 27.
    Cappuzzo, F, Magrini, E, Bartolini, S, Ceresoli, G, Ludovini, V, Gregorc, V, Ligorio, C, Lombardo, L, Crinò, L 2004Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancerProc Am Soc Clin Oncol23196(abstract 3004)Google Scholar
  28. 28.
    Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A, Fleming, T, Eiermann, W, Wolter, J, Pegram, M, Baselga, J, Norton, L 2001Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med344783792PubMedGoogle Scholar
  29. 29.
    Suo, Z, Risberg, B, Kalsson, MG, Willman, K, Tierens, A, Skovlund, E, Nesland, JM 2002EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 have different effects on survivalJ Pathol1961725CrossRefPubMedGoogle Scholar
  30. 30.
    Kurebayashi, J, Okubo, S, Yamamoto, Y, Sonoo, H 2004Inhibition of HER1 signaling pathway enhances antitumor affect of endocrine therapy in breast cancerBreast Cancer113841PubMedGoogle Scholar
  31. 31.
    Herbst, RS, Giaccone, G, Schiller, JH, Natale, RB, Miller, V, Manegold, C, Scagliotti, G, Rosell, R, Oliff, I, Reeves, JA, Wolf, MK, Krebs, AD, Averbuch, SD, Ochs, JS, Grous, J, Fandi, A, Johnson, DH 2004Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT2J Clin Oncol22785794CrossRefPubMedGoogle Scholar
  32. 32.
    Pico, C Martin, M Jara, C Barnadas, A Pelegri, A Balil, A Camps, C Frau, A Rodriguez-Lescure, A Lopez-Vega, JM DeLa Haba, J Tres, A Alvarez, I Alba, E Arcusa, A Oltra, A Batista, N Checa, T Perez-Carrion, R, GEICAM Group2004Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 studyAnn Oncol157987CrossRefPubMedGoogle Scholar
  33. 33.
    Giaccone, G, Herbst, RS, Manegold, C, Scagliotti, G, Rosell, R, Miller, V, Natale, RB, Schiller, JH, Pawel, J, Pluzanska, A, Gatzemeier, U, Grous, J, Ochs, JS, Averbuch, SD, Wolf, MK, Rennie, P, Fandi, A, Johnson, DH 2004Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1J Clin Oncol22777784CrossRefPubMedGoogle Scholar
  34. 34.
    Hainsworth, JD, Gray, JR, Morrissey, LH, Kalman, LA, Hon, JK, Greco, A 2002Long-term follow up of patients treated with paclitaxel/carboplatin based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2029372942CrossRefPubMedGoogle Scholar
  35. 35.
    Limper, AH 2004Chemotherapy-induced lung diseaseClin Chest Med255364CrossRefPubMedGoogle Scholar
  36. 36.
    Erasmus, JJ, McAdams, HP, Rossi, SE 2002Drug-induced lung injurySemin Roentgenol377281PubMedGoogle Scholar
  37. 37.
    Wong, P, Leung, AN, Berry, GJ, Atkins, KA, Montoya, JG, Ruoss, SJ, Stockdale, FE 2001Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findingsAJR Am J Roentgenol176718720PubMedGoogle Scholar
  38. 38.
    Inoue, A, Saijo, Y, Maemondo, M, Gomi, K, Tokue, Y, Kimura, Y, Ebina, M, Kikuchi, T, Moriya, T, Nukiwa, T 2003Severe acute interstitial pneumonia and gefitinibLancet361137139CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • George Fountzilas
    • 1
    • 11
  • Dimitrios Pectasides
    • 2
  • Anna Kalogera-Fountzila
    • 1
  • Dimosthenis Skarlos
    • 3
  • Haralambos P. Kalofonos
    • 4
  • Christos Papadimitriou
    • 5
  • Dimitrios Bafaloukos
    • 6
  • Stefanos Lambropoulos
    • 7
  • Savvas Papadopoulos
    • 7
  • Helen Kourea
    • 4
  • Christos Markopoulos
    • 8
  • Helen Linardou
    • 6
  • Dimitrios Mavroudis
    • 9
  • Evangelos Briasoulis
    • 10
  • Nicholaos Pavlidis
    • 10
  • Evangelia Razis
    • 7
  • Paraskevas Kosmidis
    • 7
  • Helen Gogas
    • 8
  1. 1.AHEPA HospitalAristotle University of Thessaloniki School of MedicineThessaloniki
  2. 2.Metaxa Cancer HospitalPiraeus
  3. 3.Errikos Dunant HospitalAthens
  4. 4.“RIO” HospitalUniversity of Patras School of MedicinePatras
  5. 5.Department of Clinical TherapeuticsUniversity of Athens School of MedicineAthens
  6. 6.Metropolitan HospitalPiraeus
  7. 7.Hygeia HospitalAthens
  8. 8.Laiko HospitalUniversity of Athens School of MedicineGreece
  9. 9.University Hospital, University of Crete School of MedicineIraklio
  10. 10.University of Ioannina School of MedicineIoanninaGreece
  11. 11. Medical Oncology, “Papageorgiou” Hospital,School of Medicine,Nea Efkarpia Aristotle University of Thessaloniki, School of MedicineThessaloniki Greece

Personalised recommendations